Conference Coverage
ReachMD brings you the latest research, announcements, and conversations from the most important medical conferences around the world. Join us on the conference floor with keynote speakers, experts, and opinion leaders.
226-240 of 618
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Project Oncology®From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Ryan Quigley
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
John Cho, MD, PhD, FRCPC
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Project Oncology®Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Paola Marignani, PhD, EMBA
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Project Oncology®Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
- advertisement
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Project Oncology®Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Project Oncology®Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley
David F. McDermott, MD
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Aline Fares, MD
Exploring Timing in MS Therapy: Real-World Outcomes of Fumarates
NeuroFrontiersExploring Timing in MS Therapy: Real-World Outcomes of Fumarates
Managing MS in Older Adults: Top 5 Clinical Considerations
NeuroFrontiersManaging MS in Older Adults: Top 5 Clinical Considerations
Yinan Zhang, MD
- advertisement
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
Project Oncology®Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
Samhitha Gundakaram, MBBS
What's New in Dermatology: Key Updates on Emerging Therapies
DermConsultWhat's New in Dermatology: Key Updates on Emerging Therapies
James Del Rosso, DO, FAOCD
Charles Turck, PharmD, BCPS, BCCCP
